Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Response rate and safety of standard-dose nivolumab with reduced-dose ipilimumab in metastatic melanoma.
Authors
Inderjit Mehmi
West Virginia University, Morgantown, WV
Inderjit Mehmi, Jordan Hill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 140)
DOI
10.1200/JCO.2019.37.8_suppl.140
Abstract #
140
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma
Poster
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
First Author: Paul Lorigan
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2023 ASCO Annual Meeting
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.
First Author: Faisal Fa'ak